推荐产品
agency
according to ISO 10272
品質等級
產品線
GranuCult® prime
化驗
≥98% (HPLC)
形狀
medium granules (dehydrated (DCM))
solid
製造商/商標名
Calbiochem®
GranuCult®
儲存條件
OK to freeze
protect from light
技術
microbiological culture: suitable
顏色
purple
溶解度
DMSO: 10 mg/mL
methanol: 10 mg/mL
應用
food and beverages
microbiology
pathogen testing
運輸包裝
wet ice
儲存溫度
−20°C
適合性
Listeria spp.
InChI
1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9+,18-10-,20-15+/t17-,19-,24-,25-,27+,29-/m1/s1
InChI 密鑰
AYUNIORJHRXIBJ-CQFHKJEWSA-N
一般說明
安沙霉素苯醌抗生素格尔德霉素吸水链霉菌(目录编号345805)的较低毒性,有效的合成衍生物,可与Hsp90结合(EC50 = 7.2 µM)并调节其功能。据报道可诱导凋亡并表现出抗肿瘤特性(SKBR3和MCF7细胞中的IC50分别为4.1 nM和5.2 nM)。耗尽erbB-1,erbB-2(EC50=45 nM),突变体p53(EC50=62 nM),Raf-1(EC50=80 nM)和Akt的癌症细胞。因此,抑制Ras/Raf/MEK和PI3-激酶信号通路。显示可使癌症细胞对紫杉醇(目录编号580555)和阿霉素(目录编号324380)敏感,并下调血管内皮因子的表达。
生化/生理作用
主要靶标
Hsp90
Hsp90
产物不与ATP竞争。
可逆:否
对于Hsp90,EC50 = 7.2 µM
细胞渗透性:否
包裝
用惰性气体包装
警告
毒性:标准处理(A)
重構
复溶后,等分并冷冻保存(-20°C)。储备溶液在-20°C下可稳定保存达3个月。
其他說明
Basso, A.D., et al. 2002.Oncogene21, 1159.
Clarke, P.A., et al. 2002.Oncogene19, 4125.
Clarke, P.A., et al. 2000.Oncogene19, 4125.
Schulte, T.W., and Neckers, L.M.1998.Cancer Chemother.Pharmacol.42, 273.
Schnur, R.C., et al. 1995.J. Med. Chem.38, 3806.
Clarke, P.A., et al. 2002.Oncogene19, 4125.
Clarke, P.A., et al. 2000.Oncogene19, 4125.
Schulte, T.W., and Neckers, L.M.1998.Cancer Chemother.Pharmacol.42, 273.
Schnur, R.C., et al. 1995.J. Med. Chem.38, 3806.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
GRANUCULT is a registered trademark of Merck KGaA, Darmstadt, Germany
Cancer science, 112(3), 1225-1234 (2020-12-29)
We have previously identified receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a direct transcriptional target of TTF-1/NKX2-1, a lineage-survival oncogene in lung adenocarcinoma. ROR1 sustains prosurvival signaling from multiple receptor tyrosine kinases including epidermal growth factor receptor, MET, and
eLife, 10 (2021-06-17)
Currently there is great interest in targeting mitochondrial oxidative phosphorylation (OXPHOS) in cancer. However, notwithstanding the targeting of mutant dehydrogenases, nearly all hopeful 'mito-therapeutics' cannot discriminate cancerous from non-cancerous OXPHOS and thus suffer from a limited therapeutic index. Using acute
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门